2023 DTRF Annual Report

2023 Research Workshop Presentations (cont.) Joanna Przybyl, PhD , Assistant Professor, McGill University (Canada) - “Expression of the hexosamine biosynthesis pathway components in desmoid tumors.” Yoshihiro Nishida, MD , Department of Rehabilitation Medicine and Orthopaedic Surgery, Nagoya University Hospital - “Treatment for upper limb desmoid causing pain and joint contracture: the importance of medication and rehabilitation.” J oseph Pressey, MD , Professor of Pediatrics, University of Cincinnati College of Medicine and Cincinnati Children’s Hospital Medical Center - “Percutaneous Cryoablation with and without VEGF-Tyrosine Kinase Inhibitor Therapy for Pediatric and Adult Patients with Desmoid Tumors.” Aaron Weiss, DO , Associate Professor, Department of Pediatrics, Division Chief, Pediatric Hematology-Oncology, Maine Medical Center - “A Pilot Study Evaluating the Use of Sirolimus in Children and Young Adults with Desmoid-type Fibromatosis.”

Jacob Bickels, MD , Orthopedic Oncologist, Hillel-Yaffe Medical Center - “Microbiome of desmoid tumor and its impact on the clinical course of disease.”

Ravin Ratan, MD , Associate Professor, Sarcoma Medical Oncology, MD Anderson Cancer Center - “Impact of nirogacestat on pain, a key symptom in patients with desmoid tumors (DT): Results from the phase 3 DeFi study.” Thierry Alcindor, MD , MSc, Senior Physician, Dana-Farber Cancer Institute/Harvard Medical School - “Tumor volume and T2 hyperintensity changes from DeFi: a phase 3, randomized, controlled trial of nirogacestat in patients with desmoid tumors.” Rashmi Chugh, MD , Professor, Division of Hematology/Oncology, University of Michigan Rogel Comprehensive Cancer Center - “RINGSIDE Phase 2/3 Trial of AL102 for Treatment of Desmoid Tumors (DT): Phase 2 Results.”

Researchers, clinicians, and industry professionals at DTRF Research Workshop in Philadelphia, PA

16

Made with FlippingBook Online newsletter maker